ClinicalTrials.gg
RecruitingNCT06975787Updated Oct 27, 2026

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

A Phase 1 interventional study of Vonsetamig and Odronextamab in Lupus Nephritis (LN), sponsored by Regeneron Pharmaceuticals. Recruiting at 20 sites in 6 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Oct 27, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies in Lupus Nephritis with a site in Spain — 8 open to participants now, 12 under way, 3 of them phase 3. Lupus Nephritis · Spain.

Planned enrollment
20th of 37
90 · median 100
Started
2025
with 4 others
Phase 1
4 of 39
3 open now
Primary completion
2029-09
later than 7 of 11 live
Registered
37th of 39
by date

Among the 39 studies in Lupus Nephritis with a site in Spain, this one is the 20th largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 1, reaches primary completion later than 7 of the 11 other live ones, and was the 37th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

8 of the 39 studies in Lupus Nephritis with a site in Spain are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Lupus Nephritis with a site in Spain, or all of them as a file.
02

Study summary

This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN).

The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up.

This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
03

Conditions studied

  • Lupus Nephritis (LN)

Keywords

  • Bispecific Antibodies (bsAb)
  • Double-stranded DNA (dsDNA)
  • LN class III or IV
  • Systemic Lupus Erythematosus (SLE)
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key General Inclusion Criteria:

  1. Diagnosis of Systemic Lupus Erythematosus (SLE) and LN, as described in the protocol
  2. Participant must have or relapsed disease, as described in the protocol

Key General Exclusion Criteria:

  1. History of or active severe or unstable lupus-associated neuropsychiatric disease that is likely to require acute or emergent medical treatment or hospitalization
  2. Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within 12 months prior to screening or during screening
  3. Catastrophic or severe antiphospholipid syndrome within 12 months prior to screening or during screening

NOTE: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Experimental Arm 1: Vonsetamig

    Drug: Vonsetamig

  • Experimental
    Experimental Arm 2: Odronextamab

    Drug: Odronextamab

Interventions

  • Administered as per the protocol

    Also known as: REGN5459

  • Administered as per the protocol

    Also known as: REGN1979

06

What researchers measure

Primary outcomes

  1. Occurrence of Dose Limiting Toxicities (DLT)

    Time frame: Up to 56 days

  2. Occurrence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Through week 76

  3. Severity of TEAEs

    Time frame: Through week 76

Secondary outcomes

  1. Proportion of participants no longer receiving a corticosteroid

    Time frame: At 6 months

  2. Cumulative total exposure to corticosteroids

    Time frame: At 76 weeks

  3. Absolute values of urine Protein-Creatinine Ratio (uPCR)

    Time frame: Through week 76

  4. Percent change from baseline of uPCR

    Time frame: Through week 76

  5. Absolute values of estimated Glomerular Filtration Rate (eGFR) serum creatinine

    Time frame: Through week 76

  6. Percent change from baseline of eGFR serum creatinine

    Time frame: Through week 76

  7. Absolute values of blood B-cell counts and other immune cell populations

    T cells and Natural Killer (NK) cells

    Time frame: Through week 76

  8. Change from baseline of blood B-cell counts and other immune cell populations

    T cells and NK cells

    Time frame: Through week 76

  9. Absolute values of double-stranded DNA (dsDNA) antibodies

    Time frame: Through week 76

  10. Percent change from baseline of dsDNA antibodies

    Time frame: Through week 76

  11. Absolute values of anti-Smith antibodies

    Time frame: Through week 76

  12. Percent change from baseline of anti-Smith antibodies

    Time frame: Through week 76

  13. Absolute values of anti-C1q antibodies

    Time frame: Through week 76

  14. Percent change from baseline of anti-C1q antibodies

    Time frame: Through week 76

  15. Absolute values of other autoantibodies

    anti-nucleosome

    Time frame: Through week 76

  16. Percent change from baseline of other autoantibodies

    anti-nucleosome

    Time frame: Through week 76

  17. Absolute values of Complement Factor C3 (C3) circulating factors

    Time frame: Through week 76

  18. Percent change from baseline of C3 circulating factors

    Time frame: Through week 76

  19. Absolute values of Complement Factor C4 (C4) circulating factors

    Time frame: Through week 76

  20. Percent change from baseline of C4 circulating factors

    Time frame: Through week 76

  21. Absolute values of serum levels of Immunoglobulin A (IgA)

    Time frame: Through week 76

  22. Percent change from baseline of serum levels of IgA

    Time frame: Through week 76

  23. Absolute values of serum levels of Immunoglobulin G (IgG)

    Time frame: Through week 76

  24. Percent change from baseline of serum levels of IgG

    Time frame: Through week 76

  25. Concentrations of vonsetamig in serum

    Time frame: Through week 76

  26. Concentrations of odronextamab in serum

    Time frame: Through week 76

  27. Occurence of Anti-Drug Antibodies (ADAs) to vonsetamig

    Time frame: Through week 76

  28. Occurence of ADAs to odronextamab

    Time frame: Through week 76

  29. Magnitude of ADAs to vonsetamig

    Time frame: Through week 76

  30. Magnitude of ADAs to odronextamab

    Time frame: Through week 76

07

Study locations

20 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Sep 2029, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 16, 2025
StartActual
Dec 22, 2025
Primary completionEst.
Sep 10, 2029
CompletionEst.
Sep 10, 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • University of Florida · Gainesville, United States
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    1 site added
    Show site
    • University of Florida · Gainesville, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06975787
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Dec 22, 2025
Primary completion
Sep 10, 2029 (estimated)
Completion
Sep 10, 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vonsetamig · Odronextamab

Start the discussion